Not yet recruiting
A Multicenter Study of Belantamab Mafodotin and Mezigdomide in Patients With Relapsed Multiple Myeloma
NCT07612787· Phase 1/2· Centre Hospitalier Universitaire de Saint Etienne· Source
Not yet recruiting
Study of Zanubrutinib in Older Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL)
NCT07739459· Phase 2· The Lymphoma Academic Research Organisation· Source
Not yet recruiting
FILOCLL017 - NEVOTAL : Nemtabrutinib in addition to Venetoclax-Obinutuzumab in chronic lymphocytic leukemia (CLL) / small lymphocytic leukemia (SLL) patients with TP53 ALterations
2026-525763-40-00· Phase 2· French Innovative Leukemia Organization (F.I.L.O.).· Source
Not yet recruiting
Early Corticosteroids in Severe Influenza Pneumonia, a phase III randomized controlled trial
2025-524976-40-00· Phase 3· Centre Hospital Region Metz Thionville· Source
Not yet recruiting
Prospective evaluation of response to treatment by analysis of measurable residual disease in younger adult patients (18-60 years) with acute myeloid leukemia (AML). The Backbone InterGroup (BIG)-2 umbrella trial from the Acute Leukemia French Intergroup (ALFA, FILO) - BIG2
2026-525759-96-00· Phase 4· Centre Hospitalier Universitaire De Toulouse· Source
Not yet recruiting
Fixed Duration Treatment With Combined Pirtobrutinib and Short Course Immuno-chemotherapy in Fit Patients With Previously Untreated Symptomatic Chronic Lymphocytic Leukemia (CLL).
NCT07624799· Phase 2· French Innovative Leukemia Organisation· Source
Recruiting
Phase 2 Randomized, Double-blind, Placebo-controlled Study of Prophylactic
Tocilizumab to Prevent Cytokine Release Syndrome in Relapsed/Refractory Multiple Myeloma
2025-524793-42-00· Phase 2· Janssen Cilag International· Source
Recruiting
PALETTE - Trial for personalisation of sepsis treatment in children and adults
2025-521371-31-00· Phase 2· Assistance Publique Hopitaux De Paris· Source
Not yet recruiting
A PRECISION MEDICINE RANDOMIZED TRIAL FOR PATIENTS WITH RELAPSED OR REFRACTORY T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA BASED ON A FUNCTIONAL APPROACH. ALL-TARGET TRIAL
2024-516570-30-00· Phase 2· Centre Hospitalier De Versailles· Source
Recruiting
A Study Evaluating Disease Characteristics and Outcomes in Participants With Asthma in Routine Clinical Practice
NCT07556159· Phase 4· Sanofi· Source
Not yet recruiting
Comparison of Two Etoposide Initiation Strategies for Severe Hemophagocytic Lymphohistiocytosis
NCT07497438· Phase 3· Assistance Publique - Hôpitaux de Paris· Source
Recruiting
A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy With Standard-of-Care Combination Regimens in Adult Participants With Relapsed/Refractory Multiple Myeloma (RRMM)
NCT07222761· Phase 3· Regeneron Pharmaceuticals· Source
Not yet recruiting
RASBU-SEPSIS Study: Effects of rasburicase on kidney during sepsis – a randomized, placebo-controlled, double-blind trial
2023-508071-36-00· Phase 3· Assistance Publique Hopitaux De Paris· Source
Recruiting
A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Children (6 to < 12 Years Old) With Nonsegmental Vitiligo
NCT06804811· Phase 3· Incyte Corporation· Source
Recruiting
Elranatamab/Lenalidomide Consolidation and/or Elranatamab Maintenance Versus Standard of Care After D-VRd Induction in Transplant-eligible NDMM Patients
NCT06918002· Phase 3· Intergroupe Francophone du Myelome· Source
Recruiting
MODULO
NCT06774872· Phase 3· Centre De Recherches Et D'Etudes Sur La Pathologie Tropicale Et Le Sida· Source
Recruiting
A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
NCT06588478· Phase 2· Loxo Oncology, Inc.· Source
Recruiting
A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)
NCT06428019· Phase 3· AbbVie· Source
Recruiting
Apixaban/rivaroxaban Versus Aspirin for primary prevention of thrombo-embolic complications in JAK2V617F-positive myeloproliferative neoplasms
2024-515362-13-00· Phase 2/3· Centre Hospitalier Regional Et Universitaire De Brest· Source
Recruiting
Study on Efficacy and Safety of Givinostat Versus Hydroxyurea in Patients With Polycythemia Vera
NCT06093672· Phase 3· Italfarmaco· Source
Recruiting
A Trial to Find Out if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participants With Follicular Lymphoma and Marginal Zone Lymphoma
NCT06149286· Phase 3· Regeneron Pharmaceuticals· Source
Active, not recruiting
A Trial to Learn if Odronextamab Combined With Chemotherapy is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Chemotherapy for Adult Participants With Follicular Lymphoma
NCT06097364· Phase 3· Regeneron Pharmaceuticals· Source
Active, not recruiting
Beta-lactam Intermittent Versus Continuous Infusion and Combination Antibiotic Therapy in Sepsis
NCT05681442· Phase 4· Assistance Publique - Hôpitaux de Paris· Source
Active, not recruiting
A study to test trimodulin in adult hospitalized patients with severe pneumonia
2022-501352-28-00· Phase 3· Biotest GmbH & Co. KGaA· Source
Active, not recruiting
A Phase 2 Study of Gemtuzumab Ozogamicin (GO)-Gilteritinib Combination in Adults With FLT3-ITD and/or FLT3-TKD Relapse/Refractory (R/R) AML
NCT05199051· Phase 2· Centre Antoine Lacassagne· Source
Recruiting
Evaluation of the Early Bactericidal Activity of Tedizolid and Linezolide Against Mycobacterium Tuberculosis (TEDITUB)
NCT05534750· Phase 2· Assistance Publique - Hôpitaux de Paris· Source
Recruiting
Efficacy and Safety of Subcutaneous Belimumab or Placebo in Addition of Rituximab in Persistent or Chronic Immune Thrombocytopenia
NCT05338190· Phase 3· Assistance Publique - Hôpitaux de Paris· Source
Recruiting
ASPIC - Antimicrobial Stewardship for Ventilator Associated Pneumonia in Intensive Care
2024-513327-16-00· Phase 3· Assistance Publique Hopitaux De Paris· Source
Active, not recruiting
Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
NCT04975997· Phase 3· Celgene· Source
Recruiting
Study Evaluating Combination of Luspatercept in LR-MDS Without RS Having Failed or Being Ineligible to ESA
NCT05181735· Phase 1/2· Groupe Francophone des Myelodysplasies· Source
Recruiting
De-escalation Immunotherapy mAintenance Duration Trial for Stage IV Lung Cancer Patients With Disease Control After Chemo-immunotherapy Induction
NCT05255302· Phase 2/3· Intergroupe Francophone de Cancerologie Thoracique· Source
Active, not recruiting
A Study of Rusfertide in Adults With Polycythemia Vera (PV)
NCT05210790· Phase 3· Protagonist Therapeutics, Inc.· Source
Active, not recruiting
Intravenous Immunoglobulin plus oral prednisone or high-dose dexamethasone, for adults with immune thrombocytopenia (ITP) with moderate and severe bleeding: a randomized, multicentre trial (IVIORDEX).
NCT04968899· Phase 3· Assistance Publique Hopitaux De Paris· Source
Active, not recruiting
MInimal Residual Disease Adapted Strategy
NCT04934475· Phase 3· Intergroupe Francophone du Myelome· Source
Active, not recruiting
Multicenter Open Label Phase 3 Study of Isatuximab Plus Lenalidomide and Dexamethasone With/Without Bortezomib in the Treatment of Newly Diagnosed Non Frail Transplant Ineligible Multiple Myeloma Elderly Patients (≥ 65; < 80 Years).
NCT04751877· Phase 3· Poitiers University Hospital· Source
Recruiting
Short Treatment with Omalizumab for Severe Asthma
NCT04763447· Phase 4· Assistance Publique - Hôpitaux de Paris· Source
Active, not recruiting
Study comparing two standard treatments as initial metastatic treatment among patients with visceral metastasis of ER+ HER2- breast cancer, high burden disease: chemotherapy and combination of hormonotherapy with abemaciclib.
NCT04158362· Phase 3· Unicancer· Source
Active, not recruiting
A Study of Gilteritinib Versus Midostaurin in Combination With Induction and Consolidation Therapy Followed by One-year Maintenance in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndromes With Excess Blasts-2 With FLT3 Mutations Eligible for Intensive Chemotherapy
NCT04027309· Phase 3· Stichting Hemato-Oncologie voor Volwassenen Nederland· Source
Active, not recruiting
IDH1 (AG 120) Inhibitor in Patients With IDH1 Mutated Myelodysplastic Syndrome
NCT03503409· Phase 2· Groupe Francophone des Myelodysplasies· Source
Active, not recruiting
Randomized trial evaluating the addition of nivolumab to cisplatin-radiotherapy combination for treatment of cancers of the head and neck
2024-513206-65-00· Phase 3· Groupe Oncologie Radiotherapie Tete Cou· Source
Active, not recruiting
A Study Comparing Zanubrutinib With Bendamustine Plus Rituximab in Participants With Previously Untreated CLL or SLL
NCT03336333· Phase 3· BeiGene· Source
Completed
IRinotecan and Oxaliplatin for Colon Cancer in Adjuvant Setting
NCT02967289· Phase 3· UNICANCER· Source
Active, not recruiting
Study of Tazemetostat in Newly Diagnosed Diffuse Large B Cell and Follicular Lymphoma Patients Treated by Chemiotherapy
NCT02889523· Phase 1/2· The Lymphoma Academic Research Organisation· Source
Recruiting
GRAALL2014
NCT02617004· Phase 2· Assistance Publique Hopitaux De Paris· Source